Abstract: An aqueous urethane resin dispersion for bonding can be used in wet lamination and dry lamination and can be reactivated easily at a low temperature of about 50 to 70° C. after drying, and is also superior in coatability, adhesive strength, and heat resistance. The aqueous dispersion of a polyurethane resin is superior in contact adhesiveness immediately after lamination and also has good permeability and good coatability not only on bases having smooth surfaces such as plastics and metals, but also on porous bases such as fibers, papers, and buffed leathers; an aqueous adhesive using the aqueous dispersion; and an article to which it is applied. The aqueous polyurethane resin dispersion has at least one of a sulfonate group and a carboxylate group, wherein an average particle diameter of the polyurethane resin is 0.05 to 0.30 ?m and a surface tension of the aqueous dispersion (A) is 40 mN/m or less.

Abstract: The present invention concerns a reactive carrier that forms no by-products during melt injection of polymer into articles such as sheets, films, fibers and containers. The reactive carrier is used to mix additives into the polymer resin. More particularly, the invention relates to the use of one or more cyclic anhydrides or substituted cyclic anhydrides as the reactive carrier. The polymer can be polyester or polyamide. Suitable cyclic anhydrides are those with a melt point of less than the polyester or polyamide, preferably less than about 160° C., and more preferably less than about 125° C. Most preferable are cyclic anhydrides with a melt point less than about 100° C. and especially suitable are those that are liquid at room temperature (25° C.).

Abstract: A method to form a polymeric material is disclosed. The method provides a water immiscible solvent and one or more condensation monomers, where those one or more condensation monomers are essentially insoluble in the water immiscible solvent. The one or more condensation monomers may be either a solid or a liquid at room temperature. The method forms a reaction mixture comprising a suspension of one or more solid condensation monomers, or an emulsion of one or more liquid condensation monomers, in the water immiscible solvent. The method includes heating the reaction mixture to form the polymeric material product. That polymeric material is then separated from said reaction mixture.

Abstract: A method of modifying a polymeric material whereby the polymeric material is modified to give a highly durable surface without decreasing its strength. Namely, a polymeric material is modified by the method comprising a combination of an impregnation step, an activation step, a step of grafting a monomer and a step of a treatment with a hydrophilic polymer. Thus, the hydrophilic nature, adhesiveness, and so forth of polymeric materials such as polyolefins can be improved without causing any decrease in the practical strength. The thus obtained polymeric materials are usable in articles with a need for high water absorptivity and high adhesiveness, for example, water-absorbing materials and water-retaining materials for medical, sanitary, cosmetic articles or supplies, agricultural materials, synthetic papers, filters and fiber products for clothes, for improving adhesiveness of composite materials and the like.

Abstract: A polyolefin composition suitable for preparing films and sheets, comprising: (A) from 15 to 40% by weight of a crystalline copolymer of propylene with at least one alpha-olefin of formula H2C?CHR1, where R1 is H or a C2-8 linear or branched alkyl, containing at least 90% by weight of propylene, having solubility in xylene at room temperature lower than 15% by weight; (B) from 60 to 85% by weight of an elastomeric fraction comprising: (1) a copolymer of propylene with ethylene, optionally containing 0.5 to 5% by weight of a diene, containing from 20 to 35% by weight ethylene, and having solubility in xylene at room temperature greater than 45% by weight, the intrinsic viscosity of the xylene soluble fraction ranging from 1.0 to 3.0 dl/g; and (2) a copolymer of ethylene with at least one alpha-olefin of formula H2C?CHR2, where R2 is a C2-8 linear or branched alkyl, optionally containing 0.

Abstract: Disclosed herein are low Shore A Hardness thermoplastic vulcanizate compositions having high Rebound values. In at least one exemplary embodiment, the compositions include a dispersed at least partially vulcanized rubber component; a thermoplastic component; and process oil; wherein the weight ratio of the thermoplastic component to the rubber component ranges from 80:20 to 15:85; and the thermoplastic component comprises more than 80 wt % of a polypropylene (preferably a random propylene copolymer) having a melting point less than about 105° C. The compositions can be used in molded products, consumer goods and the like.

Abstract: Styrenic resin composition comprising a rubber modified styrene maleic anhydride copolymer and polybutene. The resin is prepared by several methods including adding polybutene into the reactor, or adding polybutene to the syrup exiting the reactor and prior to entering the devolatilizer, or compounding polybutene into the polymer in an extruder after the polymer exits the devolatilizer. The polybutene ranges from 0.1 to 8% by weight and has a number average molecular weight from 900 to 2500. The rubber ranges from 4% to 20% by weight and has a particle size from 0.1 micron to 11 microns. The resin can be extruded into sheet and thermoformed into an article or can be coextruded to produce a laminated article, which may be a container for packaged foods that can be heated in microwave ovens and which container has improved toughness, elongation, and heat distortion resistance properties.

Abstract: A catalyst is preparable from a first component represented by R?C(CF2R)O?Q+ and a second component (NCCFR?)bZ. The catalyst may be combined with a fluoropolymer having nitrogen-containing cure-sites to form a curable composition that is useful for preparing fluoroelastomer compositions.

Abstract: Natural rubber and/or synthetic polyisoprene film products having enhanced tear strength and tensile strength crosslinked with a one polynitrile oxide, intended for direct or indirect contact with living tissue or fluids to be placed in living organisms.

Abstract: This invention relates to a method to support one or more catalyst compounds comprising contacting the catalyst compounds with a pretreatment agent comprising an aluminum alkyl and or an alumoxane in solution and thereafter contacting the combination with a supported activator.

Abstract: Conjugated diene polymers having good wear resistance, mechanical properties, storage stability, processability and a reduced cold flow are produced by polymerizing a conjugated diene compound with a catalyst of rare earth element compound, a compound containing at least one halogen atom, an aluminoxane, and an organoaluminum compound in an organic solvent and reacting the resulting polymer just after the polymerization with at least one compound selected from the group consisting of a halogenated organometallic compound, a halogenated metal compound, an organometallic compound, a heterocumulene compound, a hetero three-membered-ring containing compound, a halogenated isocyano compound, a carboxylic acid, an acid halide, an ester compound, a carbonic ester compound, an acid anhydride and a metal salt of a carboxylic acid as a modifying agent.

Abstract: This invention relates to a polymer of one or more C3 to C40 olefins, optionally one or more diolefins, and less than 15 mole % of ethylene, and polymerization processes for producing the same.

Abstract: A curable silicone resin composition is provided. It includes (A) an aromatic ring-containing hydrocarbon compound containing at least 2 silicon-bonded hydrogen atoms, in which the silicon atoms are bonded to the hydrocarbon skeleton; (B) an organopolysiloxane with a branched or three dimensional network structure, and with a viscosity at 25° C. of at least 1,000 mPa·s, having an average composition formula (1): R1xSiO{(4?x)/2}??(1) wherein, R1 independently represent a substituted or unsubstituted monovalent hydrocarbon group, a substituted or unsubstituted hydrocarbyloxy group, or a hydroxyl group, provided from 0.1 to 80 mol % of all the R1 groups are alkenyl groups, and x represents a positive number that satisfies 1?x<2; and (C) a hydrosilylation reaction catalyst. The composition yields a cured product that is transparent and displays excellent hardness and flexural strength.

Abstract: The present invention is directed to a non-gelled, curable composition including at least one compound having a plurality of imide functional groups. The compound in particular contains a reaction product of at least one secondary monoamine and at least one maleimide, and is suitable for use in coatings and castings.

Abstract: The invention relates to a process and composition-of-matter for the preparation of dimeric and polymeric alkylphenol polysulfides based on paracumyl phenol for use in vulcanizable rubbers in which the additive is a dimeric or polymeric alkylphenol polysulfide non-nitrosamine-releasing additive based on paracumyl phenol.

Abstract: A polyphosphazene derivative and an aromatic ring compound are bonded to one another to obtain an intermediate product. Subsequently, anhydrous sulfuric acid is added in such an amount that the molar ratio is 2 to 8 with respect to a repeating unit of the intermediate product. Further, SO3 and the intermediate product are reacted with each other to sulfonate the intermediate product. The sulfonation is performed under a condition in which the temperature range is ?20 to 0° C. and the total time is 5 to 30 hours. Accordingly, a sulfonated polyphosphazene derivative is obtained, in which the number average molecular weight is not less than 25,000 and the ion exchange capacity exceeds 3.0 mmol/g.

Abstract: Hematin, a hydroxyferriprotoporphyrin, is derivatized with one or more non-proteinaceous amphipathic groups. The derivatized hematin can serve as a mimic of horseradish peroxidase in polymerizing aromatic monomers, such as aromatic compounds. These derivatized hematins can also be used as catalysts in polymerizing aromatic monomers, and can exhibit significantly greater catalytic activity than underivatized hematin in acidic solutions. In one embodiment, polymerization is in the presence of a template, along which aromatic monomers align. An assembled hematin includes alternating layers of hematin and a polyelectrolyte, which are deposited on an electrically charged substrate. Assembled hematin can also be used to polymerize aromatic monomers.

Abstract: The subject invention provides a pharmaceutical composition comprising an aqueous carrier; from 0.1 mg/ml to 20 mg/ml of the composition of a pharmaceutically acceptable salt of a peptide having the structural formula NH2-Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Glu Glu Trp Ile Gly-COOH; and a substituted ?-cyclodextrin in an amount effective to dissolve the peptide in the aqueous carrier, wherein the composition has a pH between 4 and 9, a process for preparation, and a method of alleviating symptoms of systemic lupus erythematosus (SLE) in a human subject comprising administering to the human subject the pharmaceutical composition.

Abstract: The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of at least one disease state relative to recognition of the presence and/or the absence of the biopolymer.

Abstract: Agonist polypeptide of a receptor protein has been identified. The agonist can be used to facilitate drug and antigen absorption. Suitable routes of administration include oral, nasal, transdermal, and intravenous. Pharmaceutical formulations may comprise a therapeutic agent or an immunogenic agent in combination with the agonist polypeptide.

Abstract: The present invention is directed to novel polypeptides encoded by nucleic acids that are differentially expressed in stomach, lung and melanoma tumors.

Abstract: The present invention relates to secreted soluble ?2?-2, ?2?-3 or ?2?-4 calcium channel subunit polypeptides and their preparation, corresponding nucleic acids, recombinant vectors and host cells, as well as screening assays using same.

Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Abstract: In this invention, three genes encoding short chain neurotoxin are obtained by sea snake—Lapemis hardwickii venom gland cDNA library construction and DNA sequencing, named sn12, sn36, and sn160, respectively. The three genes are modified and amplified by PCR method, then cloned into expression vector PETTRX. The three neurotoxin genes are all highly expressed in soluble fusion protein in E. coli stain BL21-DE3 which is used as a expression host when induced with IPTG. Studies on the analgesic effects of the three recombinant short chain neurotoxins showed that three proteins, SN12, SN36 and SN160 all can significantly increase the pain threshold value of mouse.

Abstract: The invention relates to methods and reagents for diagnosing and treating diabetes.

Abstract: The invention provides vitamin k-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot formation in mammals are also described.

Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Abstract: An antibody fragment and methods of utilizing same are provided. The antibody fragment includes an antigen binding region capable of binding an extracellular portion of a P-glycoprotein thereby at least partially inhibiting drug efflux activity in multidrug resistant cells.

Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Abstract: This invention relates to a method for assessing risk of prostate cancer. Specifically, it relates to utilizing both Pro108 and Prostate Specific Antigen (PSA) in combination to determine the risk of prostate cancer. In addition, it is directed to a method for assessing risk of ovarian, colon, breast or stomach cancer utilizing Pro108 or specific antibodies to Pro108. The invention provides isolated anti-prostate, ovarian, colon, breast or stomach cancer antigen (Pro108) antibodies that bind to Pro108 on a mammalian cell in vivo. The invention also encompasses compositions comprising an anti-Pro108 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Pro108 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Pro108 antibodies. The invention encompasses a method of producing the anti-Pro108 antibodies.

Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Abstract: The present invention provides methods and compositions that may be used to modulate binding of a fibroblast growth factor (FGF) polypeptide to an FGF receptor (FGFR). In preferred embodiments, the methods and compositions of the invention modulate binding of a particular FGF polypeptide, the FGF4 polypeptide, to its receptor. The invention provides, in particular, variant FGF polypeptides that have at least one amino acid residue substitutions, insertion or deletion which alters the polypeptdies' binding affinity for an FGFR. The invention also provides models for the three-dimensional structure of a dimerized complex of FGF-FGFR-heparin. Using these models, key amino acid residues are identified and novel compounds (including novel variants of FGF and FGFR) can be identified which modulate FGF binding to its receptor. Such new compounds are therefore useful, e.g., as agonist and antagonist for FGF signaling and for bioactivities associated therewith.

Abstract: A simple and low-cost method of selectively modifying the C-terminal of a protein or peptide is provided. A method of modifying the C-terminal of a protein or peptide comprises forming an intramolecular oxazolone ring at the C-terminal of the protein or peptide that requires C-terminal modification, and then performing a ring-opening of the oxazolone ring to produce a protein or peptide with a modified C-terminal.

Abstract: The invention provides compositions comprising fragments of human telomerase reverse transcriptase (hTERT) which can lead to telomere dysfunction in a cell and reduction of growth and tumorigenicity in cancer cells. The invention also relates to uses of the fragments in the treatment of cancer and in drug discovery.

Abstract: Oligonucleotide molecules for the detection of Giardia lamblia (G. lamblia which molecules hybridise under medium to high stringency conditions to unique 18S rDNA/rRNA sequences of G. lamblia, and methods for the detection of the presence of viable cells of G. lamblia in samples using the oligonucleotide molecules.

Abstract: The present invention provides a protein having high-affinity choline transporter activity which is important physiologically, a gene encoding the protein, and a method of screening a material promoting the high-affinity choline transporter activity with the use of the same, and the like. By examining high-affinity choline uptake activity of Na+-dependent transporter cDNA deduced from the genomic sequence of a nematode (C. elegans) in a Xenopus oocyte expression system, the cDNA (cho-1) of nematode high-affinity choline transporter is identified. Then the cDNA (CHT1) of rat high-affinity choline transporter is cloned from rat spinal cord by using the homology of a base sequence to this cDNA as an index. Similarly, the cDNA of human high-affinity choline transporter is cloned from human genome.

Abstract: The present invention relates to polynucleotide molecules for regulating gene expression in plants. In particular, the present invention relates to promoters isolated from Brassica napus that are useful for regulating gene expression of heterologous polynucleotide molecules in plants. The present invention also relates to expression constructs and transgenic plants containing the heterologous polynucleotide molecules.

Abstract: The present invention relates to new nucleotide sequences coding for variable regions of ? chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses.

Abstract: The present invention feature antisense IAP oligonucleotides and other negative regulators of the IAP anti-apoptotic pathway, and methods for using them to enhance apoptosis.

Abstract: The present invention relates to highly compatible hydroxyphenyltriazine UV-absorbers and to their use in protecting plants in green houses and the protection of foodstuffs, beverages, pharmaceuticals, cosmetics, personal care products, shampoos and the like from the deleterious effects of ultraviolet radiation. It has been found that certain highly compatible tris-aryl-s-triazines are especially effective towards this end when incorporated in the containers or films in which such materials are stored.

Abstract: The invention provides aporphine and oxoaporphine compounds that may be used to manufacture a medicaments for preventing or treating vascular dysfunctions that may result in ischemic and metabolic diseases or preventing complications associated with these diseases in human and mammal. The ischemic diseases may include ischemic cerebral apoplexy, ischemic cerebral thrombosis, ischemic cerebral embolism, hypoxic ischemic encephlopathy, ischemic cardiac disease or ischemic enteropathy etc. The metabolic disease may include diabetes-induced vascular diseases, such as hypertension, atherosclerosis, peripheral artery or venous thrombosis, retinopathy and nephropathy. Methods for treating ischemic and metabolic diseases or preventing complications are also disclosed.

Abstract: Synthetic methods for preparing isomerically pure N-arylsulfonyl derivatives of proton pump inhibitors which include a substituted benzimidazole nucleus are shown by the synthetic schemes and experimental description.

Abstract: Alkylidene complexes of ruthenium containing N-heterocyclic carbene ligands and their use as highly active, selective catalysts for olefin metathesis The invention relates to a complex of ruthenium of the structural formula I, where X1 and X2 are identical or different and are each an anionic ligand, R1 and R2 are identical or different and can also contain a ring, and R1 and R2 are each hydrogen or/and a hydrocarbon group, the ligand L1 is an N-heterocyclic carbene and the ligand L2 is an uncharged electron donor, in particular an N-heterocyclic carbene or an amine, imine, phosphine, phosphite, stibine, arsine, carbonyl compound, carboxyl compound, nitrile, alcohol, ether, thiol or thioether, where R1, R2, R3 and R4 are hydrogen or/and hydrocarbon groups.

Abstract: Benzimidates can be reacted with a large number of nucleophiles, leading to a wide variety of products. The present invention discloses a facile synthesis for ethyl 2,4-dihydroxybenzimidate, and ethers and diethers thereof, from 2,4-dihydroxybenzoic acid or 2,4-dibenzyloxybenzoic acid. The present invention also discloses a method of preparing a class of iron chelating agents related to desferrithiocin, all of which contain a thiazoline ring. In this method, 2,4-dihydroxybenzonitrile is condensed with (S)-2-methylcysteine.

Abstract: A process for producing N-carboxyanhydrides is disclosed. The process produces N-carboxyanhydrides as a product and HCl as a by-product. The HCl by-product is purged from the reaction mixture by passing a purge gas through the reaction mixture as a carbonylation reagent is reacting with an amino acid or a salt thereof. The N-carboxyanhydrides produced by this process have a relatively lower chloride impurity content, relatively higher yields can be achieved, and the N-carboxyanhydrides can be produced on a larger scale.